The family of homologous enzymes known as protein kinase C (PKC) has been the object of intense interest because of its crucial role in cellular signal transduction. Although considerable information about the activation of PKC has been gained through structure-activity, molecular modeling, and synthetic studies of both natural and designed activators, information about the structure of PKC itself has been limited by its large Since the identification of its pivotal role in cellular signal transduction (1), the family of enzymes known as protein kinase C (PKC) has served as a key lead in the elucidation of normal and abnormal cellular processes. Under normal circumstances, PKC is activated by the binding of 1,2-diacyl-snglycerol (DAG, structure 1) (2-4), a second messenger released in response to the binding of extracellular agents to cell surface receptors. Differing significantly in structure from DAG, plant-derived phorbol esters (structure 2) and a diverse range of other agents (5) also bind to and activate PKC in competition with DAG but, unlike DAG, initiate a series of abnormal events associated with tumor promotion. In contrast, prostratin (structure 3), which differs from the phorbol esters only as a result of an ester deletion at the C-12 position, is not a potent promoter but exhibits cytoprotective effects in cells infected with the human immunodeficiency virus (6), a finding of potential consequence in AIDS therapy. Representative of a third structural class of activators, the marinederived macrocyclic lactone bryostatin (structure 4), now in clinical trials, binds to PKC in competition with phorbol esters but blocks a subset of phorbol ester-induced responses includ- 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. ing tumor promotion (7) (8) (9) (10) (11) (12) . Efforts to understand the structural basis for these contrasting activities, an issue of primary importance in the identification of tumor promoters and in the development of cancer prevention protocols and of medicinal leads, have focused on synthetic (13, 14) and computational (2, (15) (16) (17) (18) (19) studies of PKC activators. These studies have provided invaluable information on the common structural characteristics of activators, but delineation of the structural relationship between these activators and PKC, and consequently between normal and abnormal PKC activation, has been hampered by the lack of detailed structural information about the activator binding site on PKC. The size and physical properties of PKC along with its requirement for phospholipid cofactors in the conformation required for phorbol ester/ DAG binding (20) (21) (22) have thus far prevented structural analysis of PKC itself by crystallographic or NMR methods. To date, 11 isozymes of PKC have been identified (23) (24) (25) (26) .
The four primary subspecies of PKC (a, P3I, 3BII, and y) are large, single-chain polypeptides with four homologous (C1-C4) and five variable (V1-V5) regions (Fig. 1) . Proteolysis of PKC by trypsin (27) or calpain (28) in the V3 region produces two peptides, one of which, the "catalytic domain," contains the apparatus for protein phosphorylation, and the other of which, the "regulatory domain," retains phorbol ester/DAG-binding ability. To elucidate the structural factors involved in normal and abnormal PKC activation, we initiated a study of the synthesis, NMR analysis, and photoaffinity labeling of PKC subdomains associated with phorbol ester/DAG binding (35) . While efforts to obtain subdomains of suitable size for NMR solution structure determination through cloning have been complicated by difficulties encountered in proteolysis of fusion proteins, we have found that the desired peptides can be prepared in quantity and high purity by solid-phase synthesis. Our studies focused on the regions of greatest homology, starting with the two histidine-and cysteine-rich portions of the C1 region of rat brain PKC-,y. To prevent racemization and oxidation during synthesis, the carboxyl-terminus was extended in each case from the final cysteine to a glycine. Fig. 2 shows the final sequences which were chosen for synthesis: peptide B, incorporating aa 36-87 of the first cysteine-rich repeat, and peptide C, incorporating aa 101-151 of the second cysteine-rich repeat. This paper describes the synthesis and binding activity of these PKC subdomains and spectroscopic information on their solution behavior. (38) . The standard mixture (300 Pdl) contained 50 mM Tris/HCl buffer (pH 7.5 at 25°C), phospholipid at 0-200 ,tg/ml, 0.17% dimethyl sulfoxide, 0.2% ethanol, 2.5-50 nM QH]PDBu, bovine y-globulin at 4 mg/ml, and peptide at 0.8-15 jig/ml in a 1.5-ml Eppendorf tube. Small unilamellar phospholipid vesicles were prepared in 50 mM Tris/HCl buffer (pH 7.5) by sonication at 0°C for 1 Proc-NatL Acad Sci USA 92 (1995) 241 addition to the above mixture. Nonspecific binding was measured in the presence of 10 ,uM nonradioactive PDBu. Each sample mixture was prepared in triplicate. Samples were incubated for 30 min at 30°C in a shaker bath, removed, and cooled at 0°C for at least 5 min. The bound [3H]PDBu-peptide complex was separated from free ligand by rapid filtration through a 2.1-cm-diameter Whatman GF/B filter, pretreated with freshly prepared 0.3% polyethylenimine for a minimum of 1 hr. The sample tube was rinsed with 1 ml of ice-cold 20 mM Tris/HCl (pH 7.5), and the rinse solution was then passed through the filter. The filter was further washed with four 1-ml portions of ice-cold 20 mM Tris/HCl (pH 7.5). Each filter was then placed in a scintillation vial, 10 ml of Ecolite-(+) scintillation fluid was added, and the solution was made homogeneous by vortexing. Radioactivity (dpm) was determined with a Beckman scintillation counter. After determination of the initial radioactivity of the samples, they were stored for 48-72 hr to-allow for complete extraction of bound [3H]PDBu from the filter. Samples were then shaken, and radioactivity was again determined.
MATERIALS AND METHODS
NMR Spectroscopy. Proton NMR spectra were recorded at 400 MHz with either a Varian XL-400 or General Electric GN-400 Omega instrument operating at 20°C. Following conversion from their native formats, free inductive decays (FIDs) were processed and analyzed with FELIX 2.10 (Biosym Technologies, San Diego) on a Silicon Graphics R3000 Indigo/Elan workstation. Each FID was apodized with a 900 phase-shifted sinebell squared function before Fourier transformation.
Atomic Absorption Spectroscopy. Atomic absorption spectroscopy was carried out on a Perkin-Elmer 2380 spectrophotometer. Seven zinc standards ranging from 0-25 ng of Zn2+ per ml were prepared by diluting a commercial (Aldrich) standard solution of ZnCl2 in doubly distilled water. The response of these samples was measured to establish a calibration curve for the instrument. Protein samples in a concentration range of 10-200 ,ug of protein per ml in doubly distilled water were analyzed and compared with the calibration curve to determine zinc content.
RESULTS AND DISCUSSION Peptides B and C bound significant [3H]PDBu in the presence of phosphatidylserine without added Ca2+ at pH 7.5. Scatchard analysis gave binding constants (Kd) of 6.4 ,uM and 414 nM, respectively (Fig. 3) . For comparison, the Kd of [3H]PDBu binding to rat brain PKC (mixture of isozymes) in this assay was determined to be 2.6 nM, similar to previously reported values (38, 39 Both peptides B and C exhibited the strong requirement for phosphatidylserine (PS) characteristic of PKC (20) (21) (22) . Replacement of PS in the standard assay mixture with phosphatidylinositol, sphingomyelin, phosphatidylcholine (PC), or phosphatidylethanolamine drastically reduced or completely eliminated the ability of peptides B and C to bind [3H]PDBu. No specific binding was observed in the absence of phospholipid (Fig. 4) . Binding was maximal for both peptides at a PS concentration of 50 jig/ml and either decreased (peptide B) or remained constant (peptide C) at higher PS concentrations.
As a further test of the structural correspondence between PKC and peptide C, the ability of PS to support PDBu binding to peptide C in mixed PS/PC vesicles was also investigated. In a 1992 study, Lee and Bell (44) demonstrated that the addition of phosphatidyl-(3-hydroxypropionate), phosphatidate, phosphatidylethanol, phosphatidylglycerol, and phosphatidylinositol could cause a 2-to 5-fold reduction in the amount of PS needed to activate PKC in Triton X-100 mixed micelles (44) . This behavior was also exhibited by peptide C ( response curves were plotted for each compound, and the concentration at which 50% of [3H]PDBu binding was inhibited (IC50) determined. are visible on addition of PS, providing evidence that association with phospholipid causes an increase in the order and stability of the solution structure of the peptide. This is particularly notable in the region of the spectrum corresponding to the aromatic residues ( Fig. 6 ) and is consistent with the observed phospholipid requirement for binding of [3H]PDBu to peptides B and C, as well as to PKC itself. A recent report (34) has shown that fusion proteins incorporating sequences corresponding to our peptide C bound one to two atoms of zinc, and it was suggested that this zinc binding was required for phorbol ester binding. However, no change in the 'H NMR spectrum of peptide C was observed in our studies when one or two molar equivalents of ZnCl2 were added. In contrast, differences in the linewidth and chemical shift dispersion are generally observed in the NMR spectra of zinc-binding proteins between samples on the addition of stoichiometric quantities of Zn2+ (47, 48) . We have also performed atomic absorption experiments on HPLC-purified samples of peptide C and have found no bound zinc present. In summary, we have identified two peptides corresponding to the activator region (phorbol ester/DAG-binding domain) of several PKC isozymes that exhibit binding behavior analogous to that of PKC itself. These peptides specifically bind phorbol esters and exhibit a phospholipid dependency similar to that found for the entire protein. However, a requirement for zinc was not found, suggesting that the relationship of zinc with PKC might extend beyond the minimum phorbol ester/ DAG recognition domain. Other activators of PKC such as teleocidin B-4 and DAG were also found to bind to these peptides. Similarly, 4a-phorbol didecanoate, which differs from PE at only one stereogenic center and does not activate PKC, did not exhibit binding to these peptides. Finally, NMR analysis indicates that these peptides do not self-aggregate in solution but undergo conformational changes upon association with specific phospholipids in a fashion similar to that proposed for PKC on the basis of circular dichroism studies (49) . These observations indicate that PKC might not be preorga- nized for ligand binding (activation) except when it is in the region of the cell where its endogenous activator is generated. The similar solution and binding behavior of these peptides and PKC, coupled with their size and preliminary NMR spectra, suggests that these peptides could serve as molecular probes for the structural requirements for normal and abnormal PKC activation and for the development of new medicinal leads based on this receptor.
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